Comparative Study of the Pharmacokinetics, Efficacy and Safety of ET-26 in Elderly and Non-Elderly Subjects: The Results of a Phase I Clinical Trial

Clicks: 5
ID: 283867
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Star

Ranked #289 of 309 articles by views in Frontiers in pharmacology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 309 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Aim:To evaluate the pharmacokinetics, pharmacodynamics, and safety of the novel systemic intravenous anesthetic ET-26—an etomidate derivative designed to reduce adrenal suppression—in healthy elderly and non-elderly subjects.Methods: In this Phase I, single-center, non-randomized, open-label trial, 16 volunteers were enrolled: eight elderly (≥ 65 years, including ≥ 75 years) and eight non-elderly (18-64 years), matched for gender and body weight. Each received a standardized IV infusion of ET-26. Plasma concentrations were measured for plasma protein binding, Cmax, and AUC; time to loss of consciousness (LOC) and safety were assessed.Results: In 16 subjects (8 elderly/8 non-elderly), ET-26 showed higher exposure in the elderly (Cmax GMR 198.81%, 90%CI 126.51–312.45) and AUC0-∞ was 23.5% higher (90% CI: 107.6–141.9%) with comparable pharmacodynamics (median LOC time 1.933 min). Plasma protein binding remained stable (intergroup difference ≤1.0%). Drug-related TEAEs (37.5%) were mild and self-limiting.Conclusion: Despite elevated systemic exposure in elderly subjects, ET-26 demonstrates comparable efficacy and retains a favorable tolerability profile across age groups, eliminating the need for dose adjustments in elderly populations. Trial registration: CDE Clinical Trial Registry CTR20233784. Registered on 22 November 2023.
Reference Key
imported_1760285568_68ebd3801feaf Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Zhao, Wei
Journal Frontiers in pharmacology
Year Year not found
DOI
10.3389/fphar.2025.1665322
URL
https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1665322/full
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.